Clinical Trials

Transforming Research Into Better Lives for WM Patients

Active WM-Net Clinical Trials

Innovative studies designed and led by academic investigators to bring new treatments within reach.

WM-Net coordinates a portfolio of multi-center clinical trials investigating next-generation therapies for Waldenström’s macroglobulinemia.

Preview ongoing studies here and follow links for eligibility details and enrollment sites.

Featured
Loncastuximab tesirine in previously treated WM
WM-NET 1
Loncastuximab tesirine in previously treated WM
WM-NET 1

First trial using an ADC (antibody-drug conjugate) for WM in the world

Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Mayo Clinic, Fred Hutchinson Cancer Center

Accrual status: 20 of 21 patients

Highlight: Oral presentation at ASH 2025

Read More →
WM-NET 1
Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM
WM-NET 2
Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM
WM-NET 2

First trial using a triple combination for WM in the US

Sites: Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Colorado Blood Cancer Institute. Pending at UT Southwestern

Accrual status: 42 of 55 patients

Read More →
WM-NET 2
Epcoritamab in previously treated WM
WM-NET 3
Epcoritamab in previously treated WM
WM-NET 3

First trial using an anti-CD20 bispecific antibody for WM in the world

Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, UNC Medical Center. Pending at UT Southwestern, City of Hope

Accrual status: 5 of 20 patients

Read More →
WM-NET 3
Pirtobrutinib, Venetoclax, and Rituximab (PROVEN) in previously untreated WM
WM-NET 4
Pirtobrutinib, Venetoclax, and Rituximab (PROVEN) in previously untreated WM
WM-NET 4

First trial using a non-chemo, fixed-duration, triple combination for WM in the world

Sites: Memorial Sloan Kettering Cancer Center. Pending at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center

Accrual status: 5 of 40 patients

Read More →
WM-NET 4
Etentamig in previously treated WM
WM-NET 5
Etentamig in previously treated WM
WM-NET 5

First trial using an anti-BCMA bispecific antibody for WM in the world

Sites: Mayo Clinic, Dana-Farber Cancer Institute, MD Anderson, Memorial Sloan Kettering Cancer Center, The Ohio State University Wexner Medical Center, University of Miami Health System

Accrual Status: protocol review

Read More →
WM-NET 5
Recruiting Sustainable Digital Recruiting Sustainable Digital

Loncastuximab tesirine in previously treated WM

First trial using an ADC (antibody-drug conjugate) for WM in the world

Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Mayo Clinic, Fred Hutchinson Cancer Center

Accrual status: 20 of 21 patients

Highlight: Oral presentation at ASH 2025

Read More